The UK-based biotech company Plasticell announced a collaboration agreement with the Agency for Science, Technology and Research (A*STAR) and the Nanyang Technological University (NTU) of Singapore to progress its therapeutic stem cell pipeline. Plasticell will initially apply proprietary genome editing technology to insert functional multi-transgene cassettes into specific loci of human stem cell lines. The engineered lines will be used by Plasticell in multiple projects focused on precisely directed stem cell differentiation, phenotypic screening for drug discovery and in next-generation immuno-oncology applications.